Get the Stockscreener App
0.9997
7.44%
-0.0803
Pre-market:
1.01
0.0103
+1.03%
Inozyme Pharma Inc stock is traded at $0.9997, with a volume of 617.73K.
It is down -7.44% in the last 24 hours and down -25.95% over the past month.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
See More
Previous Close:
$1.08
Open:
$1.08
24h Volume:
617.73K
Relative Volume:
0.86
Market Cap:
$64.22M
Revenue:
-
Net Income/Loss:
$-71.17M
P/E Ratio:
-0.7192
EPS:
-1.39
Net Cash Flow:
$-70.97M
1W Performance:
-18.72%
1M Performance:
-25.95%
6M Performance:
-83.34%
1Y Performance:
-82.67%
1-Day Range:
$0.98
$1.09
1-Week Range:
$0.98
$1.29
52-Week Range:
$0.98
$7.795
Inozyme Pharma Inc Stock (INZY) Company Profile
Name
Inozyme Pharma Inc
Sector
Industry
Phone
857-330-4340
Address
321 SUMMER STREET, BOSTON
Compare INZY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
0.9997 | 64.22M | 0 | -71.17M | -70.97M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Raymond James | Outperform |
| Sep-12-24 | Initiated | Stifel | Buy |
| Aug-13-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| Mar-23-23 | Upgrade | Jefferies | Hold → Buy |
| May-26-22 | Initiated | Jefferies | Hold |
| Feb-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-29-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Inozyme Pharma Inc Stock (INZY) Latest News
Q1 EPS Estimates for Inozyme Pharma Reduced by HC Wainwright - Defense World
Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $15.00 at Needham & Company LLC - Defense World
Inozyme Pharma’s (INZY) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Piper Sandler cuts Inozyme Pharma stock target to $23 By Investing.com - Investing.com Australia
Inozyme Pharma stock hits 52-week low at $1.03 amid sharp decline - Investing.com
Piper Sandler cuts Inozyme Pharma stock target to $23 - Investing.com
H.C. Wainwright maintains Buy on Inozyme stock with $16 target By Investing.com - Investing.com Australia
Inozyme Pharma (NASDAQ:INZY) Given Outperform Rating at Wedbush - Defense World
Inozyme Pharma Focuses on ENPP1 Deficiency Program - TipRanks
Inozyme Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating - Marketscreener.com
Inozyme reports prioritization of ENPP1 Deficiency program, workforce reduction - TipRanks
Inozyme Pharma Reports 2024 Financial Results and Strategic Prioritization of ENPP1 Deficiency Program - Nasdaq
Inozyme Pharma, Inc. SEC 10-K Report - TradingView
Form 10-K Inozyme Pharma, Inc. For: Dec 31 - StreetInsider.com
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization ... - Bluefield Daily Telegraph
Inozyme Pharma Reports Full Year 2024 Financial Results and - GlobeNewswire
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights - StockTitan
Inozyme Pharma (INZY) Projected to Post Earnings on Tuesday - Defense World
Inozyme Pharma Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Rating of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Rating of “Buy” by Brokerages - Defense World
Inozyme Pharma stock hits 52-week low at $1.23 amid challenges - Investing.com Canada
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Can Inozyme's Rare Disease Pipeline Transform Bone Health Treatment? CEO Presents Key Data - StockTitan
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - The Manila Times
Inozyme Pharma to Present Recently Announced Interim Data - GlobeNewswire
Can This Rare Disease Treatment Transform Young Lives? New ENPP1 Therapy Data Emerges - StockTitan
Inozyme Pharma stock hits 52-week low at $1.32 amid market challenges - MSN
abrdn plc Makes New $472,000 Investment in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc (NASDAQ: INZY) Stock Falling -48.58% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
INZY Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
Was anything positive for Inozyme Pharma Inc (INZY) stock last session? - US Post News
Upward Trajectory: Inozyme Pharma Inc (INZY) Posts a Slidee, Closing at 1.38 - The Dwinnex
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update - MarketBeat
Barclays PLC Increases Stock Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma (NASDAQ:INZY) Price Target Cut to $30.00 by Analysts at Piper Sandler - Defense World
Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $11.00 at Wells Fargo & Company - Defense World
Inozyme Pharma (NASDAQ:INZY) Given New $11.00 Price Target at Wells Fargo & Company - MarketBeat
Inozyme shares remain Outperform at Raymond James, target reduced amid study focus - Investing.com Australia
Inozyme shares remain Outperform at Raymond James, target reduced amid study focus By Investing.com - Investing.com South Africa
Seres Therapeutics Provides Corporate Updates and Financial Results - Defense World
Inozyme Pharma Inc Stock (INZY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):